Developing TRAIL/TRAIL death receptor-based cancer therapies
Publication type: Journal Article
Publication date: 2018-03-14
scimago Q1
wos Q1
SJR: 2.596
CiteScore: 14.0
Impact factor: 8.7
ISSN: 01677659, 15737233
PubMed ID:
29541897
Cancer Research
Oncology
Abstract
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that can initiate the apoptosis pathway by binding to its associated death receptors DR4 and DR5. The activation of the TRAIL pathway in inducing tumor-selective apoptosis leads to the development of TRAIL-based cancer therapies, which include recombinant forms of TRAIL, TRAIL receptor agonists, and other therapeutic agents. Importantly, TRAIL, DR4, and DR5 can all be induced by synthetic and natural agents that activate the TRAIL apoptosis pathway in cancer cells. Thus, understanding the regulation of the TRAIL apoptosis pathway can aid in the development of TRAIL-based therapies for the treatment of human cancer.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
2
4
6
8
10
|
|
|
Cancers
10 publications, 4.88%
|
|
|
Pharmaceutics
5 publications, 2.44%
|
|
|
Frontiers in Immunology
4 publications, 1.95%
|
|
|
Frontiers in Molecular Biosciences
4 publications, 1.95%
|
|
|
Frontiers in Oncology
4 publications, 1.95%
|
|
|
Frontiers in Pharmacology
4 publications, 1.95%
|
|
|
Molecules
3 publications, 1.46%
|
|
|
International Journal of Molecular Sciences
3 publications, 1.46%
|
|
|
Biomedicine and Pharmacotherapy
3 publications, 1.46%
|
|
|
Journal of Zhejiang University: Science B
3 publications, 1.46%
|
|
|
Oncology Reports
3 publications, 1.46%
|
|
|
Oncology Letters
3 publications, 1.46%
|
|
|
Cells
2 publications, 0.98%
|
|
|
Biomolecules
2 publications, 0.98%
|
|
|
Pharmaceuticals
2 publications, 0.98%
|
|
|
Frontiers in Cell and Developmental Biology
2 publications, 0.98%
|
|
|
Frontiers in Bioengineering and Biotechnology
2 publications, 0.98%
|
|
|
Cancer Cell International
2 publications, 0.98%
|
|
|
Signal Transduction and Targeted Therapy
2 publications, 0.98%
|
|
|
Journal of Hematology and Oncology
2 publications, 0.98%
|
|
|
Apoptosis : an international journal on programmed cell death
2 publications, 0.98%
|
|
|
Cancer Letters
2 publications, 0.98%
|
|
|
Acta Biomaterialia
2 publications, 0.98%
|
|
|
International Journal of Pharmaceutics
2 publications, 0.98%
|
|
|
European Journal of Medicinal Chemistry
2 publications, 0.98%
|
|
|
Medical Oncology
2 publications, 0.98%
|
|
|
ACS Nano
2 publications, 0.98%
|
|
|
Bioengineered
2 publications, 0.98%
|
|
|
Neuro-Oncology
2 publications, 0.98%
|
|
|
2
4
6
8
10
|
Publishers
|
5
10
15
20
25
30
35
40
45
50
|
|
|
Elsevier
46 publications, 22.44%
|
|
|
Springer Nature
35 publications, 17.07%
|
|
|
MDPI
33 publications, 16.1%
|
|
|
Frontiers Media S.A.
21 publications, 10.24%
|
|
|
Taylor & Francis
12 publications, 5.85%
|
|
|
Wiley
10 publications, 4.88%
|
|
|
Spandidos Publications
6 publications, 2.93%
|
|
|
American Chemical Society (ACS)
4 publications, 1.95%
|
|
|
Royal Society of Chemistry (RSC)
3 publications, 1.46%
|
|
|
Oxford University Press
3 publications, 1.46%
|
|
|
Zhejiang University Press
3 publications, 1.46%
|
|
|
American Association for Cancer Research (AACR)
3 publications, 1.46%
|
|
|
Cold Spring Harbor Laboratory
3 publications, 1.46%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
2 publications, 0.98%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.49%
|
|
|
Bioscientifica
1 publication, 0.49%
|
|
|
IOS Press
1 publication, 0.49%
|
|
|
S. Karger AG
1 publication, 0.49%
|
|
|
Mary Ann Liebert
1 publication, 0.49%
|
|
|
Portland Press
1 publication, 0.49%
|
|
|
Baishideng Publishing Group
1 publication, 0.49%
|
|
|
King Saud University
1 publication, 0.49%
|
|
|
American Society for Biochemistry and Molecular Biology
1 publication, 0.49%
|
|
|
Georg Thieme Verlag KG
1 publication, 0.49%
|
|
|
BMJ
1 publication, 0.49%
|
|
|
American Institute of Mathematical Sciences (AIMS)
1 publication, 0.49%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 0.49%
|
|
|
eLife Sciences Publications
1 publication, 0.49%
|
|
|
IntechOpen
1 publication, 0.49%
|
|
|
5
10
15
20
25
30
35
40
45
50
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
205
Total citations:
205
Citations from 2024:
62
(30%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Yuan X. et al. Developing TRAIL/TRAIL death receptor-based cancer therapies // Cancer and Metastasis Reviews. 2018. Vol. 37. No. 4. pp. 733-748.
GOST all authors (up to 50)
Copy
Yuan X., Gajan A., Chu Q., XIONG H., Wu K., Wu G. S. Developing TRAIL/TRAIL death receptor-based cancer therapies // Cancer and Metastasis Reviews. 2018. Vol. 37. No. 4. pp. 733-748.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1007/s10555-018-9728-y
UR - https://doi.org/10.1007/s10555-018-9728-y
TI - Developing TRAIL/TRAIL death receptor-based cancer therapies
T2 - Cancer and Metastasis Reviews
AU - Yuan, Xun
AU - Gajan, Ambikai
AU - Chu, Qian
AU - XIONG, HUA
AU - Wu, Kongming
AU - Wu, Gen Sheng
PY - 2018
DA - 2018/03/14
PB - Springer Nature
SP - 733-748
IS - 4
VL - 37
PMID - 29541897
SN - 0167-7659
SN - 1573-7233
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2018_Yuan,
author = {Xun Yuan and Ambikai Gajan and Qian Chu and HUA XIONG and Kongming Wu and Gen Sheng Wu},
title = {Developing TRAIL/TRAIL death receptor-based cancer therapies},
journal = {Cancer and Metastasis Reviews},
year = {2018},
volume = {37},
publisher = {Springer Nature},
month = {mar},
url = {https://doi.org/10.1007/s10555-018-9728-y},
number = {4},
pages = {733--748},
doi = {10.1007/s10555-018-9728-y}
}
Cite this
MLA
Copy
Yuan, Xun, et al. “Developing TRAIL/TRAIL death receptor-based cancer therapies.” Cancer and Metastasis Reviews, vol. 37, no. 4, Mar. 2018, pp. 733-748. https://doi.org/10.1007/s10555-018-9728-y.